GT Biopharma (NASDAQ:GTBP) Issues Earnings Results

GT Biopharma (NASDAQ:GTBP) issued its quarterly earnings results on Friday. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.04), FiscalAI reports.

GT Biopharma Price Performance

GTBP stock traded down $0.00 during trading on Friday, hitting $0.30. 794,431 shares of the company traded hands, compared to its average volume of 449,072. GT Biopharma has a 1 year low of $0.26 and a 1 year high of $1.53. The stock’s 50-day simple moving average is $0.39 and its 200 day simple moving average is $0.42. The company has a market cap of $13.12 million, a PE ratio of -0.05 and a beta of 0.90.

Wall Street Analysts Forecast Growth

GTBP has been the topic of a number of recent analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of GT Biopharma in a research note on Wednesday, July 8th. Wall Street Zen upgraded GT Biopharma to a “hold” rating in a research note on Saturday, June 20th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, GT Biopharma currently has a consensus rating of “Sell”.

GT Biopharma Company Profile

GT Biopharma, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel immuno-oncology therapies utilizing its proprietary Tri-specific NK cell engager (TriKE) platform. This technology is designed to harness and enhance the body’s natural killer (NK) cells by simultaneously binding tumor antigens and interleukin-15 (IL-15), stimulating NK cell proliferation and targeted cytotoxicity. By focusing on NK cell engagement rather than T-cell activation, the company aims to offer therapies with potentially improved safety profiles and reduced immune-related adverse events.

The company’s lead candidate, GTB-3550, is currently in clinical trials for hematologic malignancies such as acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and myelodysplastic syndromes (MDS).